Seres Therapeutics, Inc.
MCRBHealthcare|Biotechnology|US
$1.98
-0.11 (-5.26%)
Tangible Book / Share
$2.14
Cash / Share
$1.76
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT03183141 ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection | Clostridioides Difficile Infection | P3 | Completed | 263 | Open-label | SER-109 |
| NCT03183128 ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection | Clostridium Difficile Infection | P3 | Completed | 182 | RCT, Double-blind | SER-109, Placebo |
| NCT03759041 A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis | Ulcerative Colitis | P2 | Terminated | 203 | RCT, Double-blind | Vancomycin Pre-Treatment, Placebo for Vancomycin Pre-Treatment, SER-287, Placebo for SER-287 |
| NCT02437487 SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) | Clostridium Difficile | P2 | Completed | 89 | RCT, Double-blind | SER-109, Placebo |
| NCT03817125 Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention | Metastatic Melanoma | P1 | Completed | 14 | RCT, Double-blind | Placebo for antibiotic, Vancomycin pretreatment, Nivolumab, Matching Placebo for SER-401, SER-401 |
| NCT02830542 SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence | Clostridium Difficile Infection | P1 | Completed | 96 | RCT, Double-blind | SER-262, Placebo |
| NCT02618187 A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis | Ulcerative Colitis | P1 | Completed | 58 | RCT, Double-blind | SER-287, Placebo, Placebo Pre-Treat, Vancomycin Pre-Treat |
| NCT04995653 A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT | Allogeneic Hematopoietic Stem Cell Transplantation | P1 | Completed | 60 | RCT, Double-blind | Vancomycin Pre-Treatment, Vancomycin Placebo, SER-155, SER-155 Placebo |
| NCT02437500 Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI) | Clostridioides Difficile Infection | APPROVED_FOR_MARKETING | — | — | SER-109 |